An observational study of nearly 35,000 Scandinavian patients with type 2 diabetes (T2D) has found sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of prescription drugs approved by the FDA to lower blood sugar in adults with T2D, may almost double patients’ risks of lower limb amputation and diabetic ketoacidosis compared to glucagon-like peptide 1 (GLP1) receptor agonists.

Heart patients with symptoms of peripheral artery disease (PAD) continue to see low rates of prescriptions for antiplatelets, statins and ACE inhibitors, despite those drugs’ potential to prevent against major events like stroke, according to research published Nov. 15 in Stroke.

A machine learning-based risk calculator developed to assess an individual’s long-term risk for atherosclerotic cardiovascular disease (ASCVD) identified 13 percent more high-risk patients and recommended unnecessary statin therapy 25 percent less often than standard risk assessment tools in initial tests, researchers reported in the Journal of the American Heart Association.

A new study published in Circulation emphasized the importance of prompt arterial switch operations (ASOs) for infants with transposition of the great arteries, as neonates more than 6 days old were 90 percent more likely to die in the perioperative period.

The idea of “rapid and complete recovery” in Takotsubo patients is a myth, according to research published in the Nov. 7 edition of the European Heart Journal—and it’s one physicians should be paying more attention to.

A decades-long study of patients who have migraines with visual aura has linked the painful headaches to an increased risk of experiencing atrial fibrillation and, to a lesser degree, stroke, researchers report in the online edition of Neurology.

A study of two neighboring communities living in the remote Venezuelan rainforest is poking holes in the idea that blood pressure inevitably increases with age.

Results of the CIRT trial presented at the American Heart Association Scientific Sessions dimmed hopes that low-dose methotrexate can reduce cardiovascular events but furthered researchers’ understanding of which inflammation-targeting therapies might succeed in that regard.